

Obesity is associated with a higher level of pro-inflammatory cytokines in follicular fluid of women undergoing medically assisted procreation (PMA) programs

S. LA VIGNERA, R. CONDORELLI, S. BELLANCA, B. LA ROSA,
A. MOUSAVÍ, B. BUSÀ, L.O. VICARI, E. VICARI

Department of Internal Medicine and Systemic Diseases, Section of Endocrinology, Andrology and Internal Medicine and Master in Andrological, Human Reproduction and Biotechnology Sciences, University of Catania, Catania (Italy)

Abstract. – Introduction: Cytokines are glycoproteins that modulate reproductive function through a series of various mechanisms (by both conditioning gonadal steroidogenesis and contributing to the preservation of an inflammatory microenvironment).

Aim of the Study: To evaluate the impact of certain clinical variables (i.e., age, obesity, insulin resistance index, serum antithyroid antibodies serum levels) on the serum concentrations of cytokines TNF-alpha, IL-6, and IL-10 in the follicular fluid of women undergoing a medically assisted procreation (PMA) cycle.

Materials and Methods: A total of 40 female patients undergoing an intracytoplasmic sperm injection (ICSI) in oocytes, following ovarian stimulation by purified FSH and hCG carried out after suppression of ovarian function. The follicular fluid, obtained by surgical ultrasonography-guided withdrawal, was stored at -30 degrees C. Subsequently the cytokines were assayed by ELISA technique.

Results: Women suffering from class II obesity showed follicular levels of TNF-alpha significantly higher ($p < 0.05$) than women with a normal body mass index (BMI). Significantly higher concentrations of TNF-alpha and IL-6 were found in women with HOMA index > 2.5 . Women clinically presenting with concomitant obesity and high serum levels of antithyroid antibodies were found to have higher follicular levels of TNF-alpha and IL-6 ($p < 0.05$) in comparison with women suffering from obesity only or low antithyroid antibodies levels only, or from both these conditions.

Conclusion: Obesity is a common clinical condition associated with a higher concentration of inflammatory substances in the follicular fluid of infertile women. It is not understood, as yet, the possible pejorative role exerted by the presence of other clinical conditions, such as insulin resistance and high levels of antithyroid antibodies, that are conditions frequently encountered in the clinical practice.

Key Words:

Cytokines, Follicular fluid, Obesity, Assisted procreation programs.

Introduction

Ovarian function can be influenced by the biological action of cytokines, which are able to interfere with the signal coming from the pituitary gland as well as from the locally generated ovulatory phase, the luteal phase and the steroidogenesis. A regulatory effect by interleukin 1 (IL-1) and tumor necrosis factor-alpha (TNF- α) on the pituitary axis has been documented, both *in vitro* and *in vivo*. In fact, in the experimental animal, IL-1 administration can suppress GnRH release. In addition, IL-1 shows a direct action (i.e., inhibition) on testicular and ovarian steroidogenesis. IL-1 inhibitory effects are potentiated by TNF. Similar effects to those produced by IL-1 are ascribed to IFN-gamma¹⁻⁷.

TNF- α influences sexual hormone biosynthesis, by modulating receptor function of gonadotropins and by modifying ovarian folliculogenesis⁸⁻¹⁰. TNF- α , in association with IFN-gamma, decreases estradiol and progesterone secretions from luteal cells¹¹⁻¹⁴. *In vivo* studies show the presence of higher levels of TNF- α in the follicular fluid of women with infertility of immune origin, as compared with other women presenting with an isolated tubal factor¹⁵.

IL-6 is characterized by a pleiotropic action and by its involvement in the regulation of immune response¹⁶. *In vitro* studies indicate that its produc-

tion is balanced by IL-1 alpha/beta production, whereas it is not influenced by TNF-alpha and is inhibited by IFN-gamma¹⁷. This cytokine could be involved in the mechanism of oocyte selection¹⁸ and its concentration in follicular fluid appears to be related with the degree of oocyte maturation¹⁹. The increase in IL-6 level in the follicular fluid of women with an immunologic factor of infertility reflects a function of modulation and functional antagonism towards TNF- α ^{20,21}. Cytokine production in the follicular fluid is a clear example of self-regulation aimed at decreasing the impact of a pronounced inflammatory response due to high levels of TNF- α ; such findings are typically found in women with immune infertility¹⁵.

IL-10 reflects an immunosuppressant function, with a functional antagonism towards the main pro-inflammatory cytokines (i.e., IFN-gamma and TNF- α)²². It is not entirely clear the biological role of IL-10 in the follicular fluid, with special reference to its possible involvement in folliculogenesis²³. A recent study by Cerkiene et al²⁴ carried out on 121 women shows that IL-10 follicular levels fail to interfere with the outcome of medically assisted procreation (PMA) programs. Although a decreased local production of IL-10, as a result of high TNF- α high levels, appears to be one of the mechanisms involved in generating infertility of immune origin.

Based on these data, we evaluated the concentrations of three different cytokines, i.e. TNF- α , IL-6 and IL-10, in the follicular fluid of obese women undergoing a medically assisted procreation (PMA) cycle, in relation to certain clinical variables, such as age, body mass index (BMI), insulin resistance index and antithyroid antibodies serum levels.

Material and Methods

A total of 40 women from 28 to 43 years old (mean age: 34 years) were selected and then enrolled in the study after obtaining their signed informed consent. All the women afferent for couple infertility, in particular secondary to isolated tubal pathology in 10 cases (25%), chronic anovulation in 6 cases (15%), cervical inflammation in 8 cases (20%), documented male factor in 8 cases (20%), and apparent idiopathy in the remaining 8 cases (20%). After their physical examination, the women were grouped into clinical categories according to the following parameters:

age, BMI (kg/m²), insulin resistance index, presence or absence of serum antithyroid antibodies. After the initial endocrinologic evaluation, all the women underwent the following fasting blood tests: glycemia [enzymatic method; Roche Diagnostics, Monza (MI), Italy], insulin [ECLIA; Roche Diagnostics, Monza (MI), Italy] for determining HOMA index (fasting blood glucose (nmol/l) \times basal insulin (nmol/l)/22.5)²⁵ and serum antithyroid antibodies [ECLIA; Roche Diagnostics, Monza (MI), Italy]. Following ovarian axis suppression by GnRH analogue (*Decapeptyl*[®] Ipsen S.p.A., Milan, Italy), all the women were treated with purified FSH (*Puregon*[®] Organon Italia, Rome, Italy) and hCG (*Gonasi HP*[®] Amsa, Rome, Italy) according to a superovulation protocol. Following ovarian pick-up, aliquots of follicular fluid were stored at -30 degrees C and IL-6, IL-10 and TNF-alpha levels were assayed by ELISA technique (sandwich ELISA R&D System Europe Ltd, Abingdon, UK). The protocol was approved by Institutional Ethics Committee and all patients signed informed consent.

Clinical Criteria for Exclusion

Autoimmune factors, endometriosis.

Clinical Criteria for Inclusion

Concerning to the couple – desire to procreate of at least two years duration, recurrent failure following induction of ovulation and planned sexual intercourse, failure of fecundation following first level technique (3-6 months);

Congerning to the woman – severe peritoneal factor, poor oocyte response following therapy with high doses of gonadotropins (<3 oocytes or >40 years old with <5 oocytes); and

Concernig to the man – severe oligospermia including cases of cryptozoospermia, severe or total asthenozoospermia, severe or total teratozoospermia, retrograde ejaculation.

Follicular Fluid Withdrawal

Follicular fluid withdrawal was carried out by transvaginal route under ultrasonographic guide (Esaote GPX, Genova, Italy, Megas, 7.5 MHz, biplane biconvex probe). Each follicle was separately suctioned, collected into a 15-ml test tube and dipped into the culture medium. Following hCG administration, the follicles showed a mean 16 mm diameter, the mean estradiol concentration was 7.1 \pm 0.6 nmol/l. Oocyte recovery took place 36 hours following hCG administration.

Table I. Concentration of cytokines in ovarian follicular fluid in relation to age of patients.

Group	Age	Number of patients	IL 6 (pg/ml)	TNF- α (pg/ml)	IL 10 (pg/ml)
1	< 30	6	17.1 \pm 1.6	19.1 \pm 2.1	6.3 \pm 0.6
2	30-35	15	21.7 \pm 1.3	27.6 \pm 2.5*	2.9 \pm 0.3
3	35-40	12	14.9 \pm 1.7	16.3 \pm 1.9	3.7 \pm 1.1
4	> 40	7	18.4 \pm 2.5	19.6 \pm 3.2	3.1 \pm 1.1

Values expressed as mean \pm SEM.

Statistical Analysis

Statistical analysis was obtained by means of ANOVA followed by the use of Newman Keuls test (SNK). *P* values <0.05 were considered as a statistically significant difference.

Patients with BMI >25 kg/m² and concomitant positive serum antithyroid antibodies showed intrafollicular TNF- α and IL-6 levels significantly higher (*p* <0.05) compared to patients with isolated obesity and/or negative antithyroid antibodies (Table V).

Results

Patients were divided into 4 groups according to age (<30 years, 30-35 years, 35-40 years, >40 years). Patients belonging to the 30-35 years age group showed intrafollicular TNF- α levels significantly higher (*p* <0.05) compared to patients belonging to 35-40 years age group.

Patients were divided also into 4 groups according to BMI (i.e., 18.5-24.9; 25-29.9; 30-34.9; 35-39.9 kg/m²); the patients with a BMI between 35 and 39.9 kg/m² showed intrafollicular TNF- α levels significantly higher (*p* <0.05) compared to remaining groups (Table II).

Patients with a HOMA index >2.5 showed intrafollicular IL-6 and TNF- α levels significantly higher (*p* <0.05) compared to patients with a HOMA index <2.5 (Table III).

No significant differences were found between patients with positive or negative serum antithyroid antibodies (Table IV).

Discussion

Obesity and Female Reproduction

Female obesity is associated with higher risk of pathological endocrine conditions, such as amenorrhoea and infertility^{26-30;33,34}. In addition, obesity influences negatively the outcome of medical treatments for infertility^{32,35}. The risk of a miscarriage following fertilization is higher in obese women³¹. Hormonal profile, especially when there is a concomitant amenorrhoea, is characterized by a high rate of hyperandrogenism, increased aromatization, altered production of proteins that are linked to sexual hormones²⁶⁻³⁵. The present study confirms that obesity is a clinical condition associated with worse reproductive profile^{36,37}; as demonstrated by higher rate of intrafollicular oxidative stress which was observed before fertilization in a group of patients undergoing to medically assist-

Table II. Concentration of cytokines in ovarian follicular fluid in relation to body mass index of patients.

Group	Body mass index	Number of patients	IL 6 (pg/ml)	TNF- α (pg/ml)	IL 10 (pg/ml)
1	18.5-24.9	8	14.2 \pm 0.6	15.2 \pm 0.6	4.8 \pm 0.9
2	25-29.9	16	20.5 \pm 0.7*	23.1 \pm 0.6	4.4 \pm 1.1
3	30-34.9	10	21.1 \pm 1.9*	24.7 \pm 1.3	2.8 \pm 0.7
4	35-39.9	6	23.1 \pm 0.8*	29.8 \pm 2.5*	2.7 \pm 0.5

Values expressed as mean \pm SEM.

Table III. Concentration of cytokines in ovarian follicular fluid in relation to HOMA index of patients.

Group	HOMA index	Number of patients	IL 6 (pg/ml)	TNF- α (pg/ml)	IL 10 (pg/ml)
1	> 2.5	14	22.8 \pm 0.4*	22.2 \pm 1.7*	3.9 \pm 0.2
2	< 2.5	26	15.7 \pm 0.8	16.3 \pm 1.1	5.4 \pm 0.6

Values expressed as mean \pm SEM.

Table IV. Concentration of cytokines in ovarian follicular fluid in relation to positivity or negativity serum thyroid antibodies.

Group	AAT ATPO	Number of patients	IL 6 (pg/ml)	TNF- α (pg/ml)	IL 10 (pg/ml)
1	++	10	19.7 \pm 1.9	23.1 \pm 2.9	2.8 \pm 0.5
2	+/-	10	16.6 \pm 3.3	18.2 \pm 3.8	3.9 \pm 2.1
3	-/-	20	16.1 \pm 1.1	17.9 \pm 1.5	5.4 \pm 0.8

Values expressed as mean \pm SEM.

ed procreation³⁸. In particular, insulin resistance is associated with proinflammatory balance of cytochemical ovarian microenvironment³⁹. Insulin resistance is a consequence of obesity, and in women it is often linked with ovarian function leading to clinical reproductive manifestations such as early menarche onset, subfertility and polycystic ovary syndrome⁴⁰. Likewise, the dramatic fall in oestrogen production after menopause may contribute to weight gain and changes in adipose tissue distribution⁴¹. Overall, women who are obese, especially those with reproductive complications including polycystic ovary syndrome, have been identified as specific high risk subgroups for further progression through to impaired glucose tolerance, type 2 diabetes mellitus and potentially cardiovascular disease⁴². Obese women exhibit an altered ovarian follicular environment, particularly increased metabolite, C-reactive protein, and androgen ac-

tivity levels, which may be associated with poorer reproductive outcomes typically observed in these patients⁴³.

Thyroid and Female Reproduction

The presence of high serum levels of antithyroid antibodies may be associated with a premature interruption of pregnancy as well as a failure in medically assisted procreation⁴⁴⁻⁴⁷. Furthermore, antithyroid antibodies positivity is often found in healthy women, who have never suffered from thyroid disease in the past. Studies carried out by Geva et al. showed that the rate of patients presenting with positive antithyroid antibodies was very high among infertile women. Moreover, a low number of them was successfully treated with medically assisted procreation. In 1998, Kim et al. reported that patients with positive serum antithyroid antibodies, together with either a tubal factor or an unclear infertility fac-

Table V. Concentration of cytokines in ovarian follicular fluid in obese patients and associated serum thyroid antibodies positivity.

Group	Clinical profile	Number of patients	IL 6 (pg/ml)	TNF- α (pg/ml)	IL 10 (pg/ml)
1	S + TA	18	21.1 \pm 1.1*	23.1 \pm 2.9*	4.1 \pm 1.9
2	O + TA	10	23.1 \pm 0.4*	28.5 \pm 1.9*	2.5 \pm 0.3
3	N/NTA	12	15.3 \pm 0.8	16.9 \pm 1.1	4.7 \pm 0.7

Values expressed as mean \pm SEM. OW = overweight; O = obesity; TA = thyroid antibodies; N = normal weight; NTA = negatives for thyroid antibodies.

tor, showed a lower rate of success following the application of medically assisted procreation. Although a series of controversial data are found in the literature on such a subject, a relative influence is generally accepted^{46, 48-54}, the antioxidant enzymatic or not systems become altered during thyroid dysfunction⁵⁵. During autoimmune thyroid dysfunction, in particular Basedow's disease, it has been observed that monocyte and macrophage activation cause an increased IL-1, IL-10 and TNF-alpha production⁵⁶. The data obtained in the present study support an antithyroid antibodies role as a possible co-factor capable of contributing to increase the rate of oxidative stress in ovarian microenvironment, in combination with a traditional risk factor as obesity. Instead, the isolated presence of such antibodies is not associated with an increase in pro-inflammatory ovarian cytokine concentration.

References

- 1) CRAVA M, CANTELL K, VIHKO R. Human leukocyte interferon inhibits human chorionic gonadotropin stimulated testosterone production by porcine Leydig cells in culture. *Biochem Biophys Res Commun* 1985; 127: 809-815.
- 2) RIVIER C, RIVEST S. Effect of stress on the activity of the hypothalamic- pituitary-gonadal axis: peripheral and central mechanisms. *Biol Reprod* 1991; 45: 523-532.
- 3) SHALTS E, FENG YL, FERIN M. Vasopressin mediates the interleukin-1 alpha induced decrease in luteinizing hormone secretion in the ovariectomized rhesus monkey. *Endocrinology* 1992; 131: 153-158.
- 4) KALRA PS, FUENTES M, SAHU A, KALRA SP. Endogenous opioid peptides mediate the interleukin-1 inhibition of luteinizing hormone (LH)-releasing hormone and LH. *Endocrinology* 1990; 127: 2381-2386.
- 5) KALRA PS, SAHU A, KALRA SP. Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats. *Endocrinology* 1990; 126: 2145-2152.
- 6) KAUPPILA A, CANTELL K, JANNE O, KOKKO E, VIHKO R. Serum sex steroid and peptide hormone concentrations and endometrial estrogen and progesterone receptor levels during administration of human leukocyte interferon. *Int J Cancer* 1982; 29: 291-294.
- 7) CALKINS JH, SIGEL NM, NANKIN HR, LIN T. Interleukin-1 inhibits Leydig cell steroidogenesis in primary culture. *Endocrinology* 1998; 123: 1605, 1998.
- 8) ADASHI EY, RESNICK CE, CROFT CS, PAYNE DW. TNF alpha inhibits gonadotropin hormonal action in non-transformed ovarian granulosa cells. A modulatory non-cytotoxic property. *J Biol Chem* 1989; 264: 11591-11597.
- 9) ADASHI EY. The potential relevance of cytokines to ovarian physiology : the emerging role of resident ovarian cells of the white blood cell series. *Endocr Rev* 1990; 11: 454-464.
- 10) ADASHI EY, RESNICK CE, PINKMAN NJ, HURWITS A, PAYNE DW. Cytokine mediated regulation of ovarian function: TNF alpha inhibits gonadotropin supported-progesterone accumulation by differentiating and luteinized murine granulosa cells. *Am J Obstet Gynecol* 1990; 162: 889-899.
- 11) FUKUOKA M, YASUDA K, FUJIWARA H, KANZAKI H, MORI T. Interaction between IFN gamma, TNF alpha, and IL-1 modulating progesterone and oestradiol production by human luteinized granulosa cells in culture. *Hum Reprod* 1992; 7: 1361-1364.
- 12) WANG HZ, LU SH, HAN XJ, ZHOU W, SHENG WX, SUN ZD, GONG YT. Inhibitory effect of IFN and TNF on human luteal function in vitro. *Fertil Steril* 1992; 58: 941-945.
- 13) CHAE H, HONG SH, HONG SH, KIM CH, KANG BM, LEE YJ. Influence of TNF alpha on estradiol, progesterone, insulin-like growth factor-II, and insulin-like growth factor binding protein 1,2 and 3 in cultured human luteinized granulosa cells. *Eur J Obstet Gynecol Reprod Biol* 2007; 131: 176-181.
- 14) SAKUMOTO R, SHIBAYA M, OKUDA K. TNF alpha inhibits progesterone and estradiol-17 beta production from cultured granulosa cells: presence of TNF alpha receptors in bovine granulosa and theca cells. *J Reprod Dev* 2003; 49: 441-449.
- 15) CIANCI A, CALOGERO AE, PALUMBO MA, BURRELLO N, CIOTTA L, PALUMBO G, BERNARDINI R. Relationship between TNF alpha and sex steroid concentrations in the follicular fluid of women with immunological infertility. *Hum Reprod* 1996; 11: 265-268.
- 16) BENDTZEN K. Immune hormones (cytokines): pathogenic role in autoimmune, rheumatic and endocrine disease. *Autoimmunity* 1989; 4 : 177-189.
- 17) GOROSPE WC, SPANGELO BL. IL-6 production by rat granulosa cells in vitro: effects of cytokine, follicle-stimulating hormone and cyclic 3',5'-adenosine monophosphate. *Biol Reprod* 1993; 48: 538-543.
- 18) MAEDA A, INOUE N, MATSUDA-MINEHATA F, GOTO Y, CHENG Y, MANABE N. The role of interleukin-6 in the regulation of granulosa cell apoptosis during follicular atresia in pig ovaries. *J Reprod Dev* 2007; 53: 481-490.
- 19) KAWASAKI F, KAWANO Y, KOSAY HASAN Z, NARAHARA H, MIYAKAWA I. The clinical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids. *Clin Exp Med* 2003; 3: 27-31.
- 20) GOROSPE WC, HUGHES FM Jr, SPANGELO BL. IL-6: effects and production by rat granulosa cells in vitro. *Endocrinology* 1992; 130: 1750-1752.

- 21) TIG H, TREHU E, ATKINS MB, DINARELLO CA, MIER JW. IL-6 is an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble TNF receptor p55. *Blood* 1994; 83: 113-118.
- 22) MOORE KM, GARRA AO, DE WAAL MALEFYT R, Vieira P, Mosmann TR. IL 10. *Annu Rev Immunol*, 1993; 11: 165-190.
- 23) GEVA E, LESSING JB, LERNER-GEVA L, AZEM F, YOVEL I, BEN-YOSEF D, BARKAI U, AMIT A. Interleukin-10 in preovulatory follicular fluid of patients undergoing in-vitro fertilization and embryo transfer: *Am J Reprod Immunol* 1997; 37: 187-190.
- 24) CERKIENE Z, EIDUKAITE A, USONIENE A. Follicular fluid levels of interleukin-10 and interferon gamma do not predict outcome of assisted reproductive technologies. *Am J Reprod Immunol* 2008; 9: 118-126.
- 25) MATTHEWS DR, HOSKER JP, RUDENSKY AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostatis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412-419.
- 26) LAKE JK, POWER C, COLE TJ. Women's reproductive health: the role of body mass index in early and adult life. *Int J Obes Relat Metab Disord* 1997; 21: 432-438.
- 27) RICH-EDWARDS JW, GOLDMAN MB, WILLETT WC, HUNTER DJ, STAMPFER MJ, COLDITZ GA, MANSON JE. Adolescent body mass index and infertility caused by ovulatory disorder. *Am J Obstet Gynecol* 1994; 171: 171-177.
- 28) ROGERS J, MITCHELL GW. The relation of obesity to menstrual disturbances. *N Engl J Med* 1952; 247: 53-55.
- 29) GREEN BB, WEISS NS, DANLING JR. Risk of ovulatory infertility in relation to body weight. *Fertil Steril* 1998; 50: 721-726.
- 30) RICH-EDWARDS JW, MANSON JE, GOLDMAN MB. Body mass index at age 18 years and the risk of subsequent ovulatory infertility. *Am J Epidemiol* 1992; 5: 247-250.
- 31) FEDORCSAK P, STORENG R, DALE PO, TANBO T, ABYHOLM T. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. *Acta Obstet Gynecol Scand* 2000; 79: 43-48.
- 32) CLARK AM, THORNLEY B, TOMLINSON L, GALLETLEY C, NORMAN RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod* 2008; 13: 1502-1505.
- 33) PASQUALI R, GAMBINERI A. Metabolic effects of obesity on reproduction. *Reproductive Biomedicine online*. 2006;12: 542-51.
- 34) PASQUALI R, PATTON L, GAMBINERI A. Obesity and infertility. *Current Opin Endocrinol Diabetes Obes* 2007; 14: 482-487.
- 35) ZAIN MM, NORMAN RJ. Impact of obesity on female fertility and fertility treatment. *Womens Health (Lond, Engl)* 2008; 4: 183-194.
- 36) WILKES S, MURDOCH A. Obesity and female fertility: a primary care perspective. *J Fam Plann Reprod Health Care* 2009; 35: 181-185.
- 37) LORET DE MOLA JR. Obesity and its relationship to infertility in men and women. *Obstet Gynecol Clin North Am* 2009; 36: 333-346.
- 38) SAJAL G, NEENA M, DIPIKA S, ANJALI C, AGARWAL A. Oxidative stress and its role in female infertility and assisted re production: clinical implications. *Int J Fertil Steril* 2009; 2: 147-164.
- 39) AMATO G, CONTE M, MAZZIOTTI G, LALLI E, VITOLO G, TUCKER A, BELLASTELLA A, CARELLA C, IZZO A. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. *Obstet Gynecol* 2003; 101: 1177-1182.
- 40) AKAMINE EH, MARÇAL AC, CAMPOREZ JP, HOSHIDA MS, CAPERUTO LC, BEVILACQUA E, CARVALHO CR. Obesity induced by high-fat diet promotes insulin resistance in the ovary. *J Endocrinol* 2010; 206: 65-74.
- 41) KELLER C, LARKEY L, DISTEFANO JK, BOEHM-SMITH E, RECORDS K, ROBILLARD A, VERES S, AL-ZADJALI M, O'BRIAN AM. Perimenopausal obesity. *J Womens Health (Larchmt)* 2010; 19: 987-996.
- 42) ROBKER RL, AKISON LK, BENNETT BD, THRUPP PN, CHURRA LR, RUSSELL DL, LANE M, NORMAN RJ. Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. *J Clin Endocrinol Metab* 2009; 94: 1533-1540.
- 43) AKAMINE EH, MARÇAL AC, CAMPOREZ JP, HOSHIDA MS, CAPERUTO LC, BEVILACQUA E, CARVALHO CR. Obesity induced by high-fat diet promotes insulin resistance in the ovary. *J Endocrinol* 2010; 206: 65-74.
- 44) KAPRARA A, KRASSAS GE. Thyroid autoimmunity and miscarriage. *Hormones (Athens)* 2008; 7: 294-302.
- 45) TODOROVA K, GENOVA M, KONOVA E. Frequency of miscarriages among pregnant women with autoimmune thyroid disorders. *Akush Ginekol (Sofia)* 2008; 47: 16-20.
- 46) PUTOWSKI L, DARMOCHWAL-KOLARZ D, ROLINSKI J, OLESZCZUK J, JAKOWICKI J. The immunological profile of infertile women after repeated IVF failure (preliminary study). *Eur J Obstet Gynecol Reprod Biol* 2004; 112: 192-196.
- 47) GHAZEERI GS, KUTTEH WH. Autoimmune factors in reproductive failure. *Curr Opin Obstet Gynecol* 2001; 13: 287-291.
- 48) GEVA E, VARDINON N, LESSING JB, LERNER-GEVA L, AZEM F, YOVEL I, BURKE M, YUST I, GRUNFELD R, AMIT A. Organ-specific autoantibodies are possible markers for reproductive failure: a prospective study in an in-vitro fertilization-embryo transfer programme. *Hum Reprod* 1996; 11: 1627-1631.
- 49) KIM CH, CHAE HD, KANG BM, CHANG YS. Influence of antithyroid antibodies in euthyroid women on in vitro fertilization-embryo transfer outcome. *Am J Reprod* 1998; 14: 2886-2890.

- 50) KUTTEH WH, SCHOOLCRAFT WB, SCOTT RT Jr. Antithyroid antibodies do not affect pregnancy outcome in women undergoing assisted reproduction. *Hum Reprod* 1999; 14: 2886-2890.
- 51) RABER W, NOWOTNY P, VYTISKA-BINSTORFER E, VIERHAPPER H. Thyroxine treatment modified in infertile women according to thyroxine-releasing hormone testing: 5 year follow-up of 283 women referred after exclusion of absolute causes of infertility. *Hum Reprod* 2003; 18: 707-714.
- 52) POPPE K, VELKENIERS B. Thyroid disorders in infertile women. *Ann Endocrinol (Paris)* 2003; 64: 45-50.
- 53) POPPE K, VELKENIERS B, GLINOER D; MEDSCAPE. The role of thyroid autoimmunity in fertility and pregnancy. *Nature clinical practice. Endocrinol Metab* 2008; 4: 394-405.
- 54) NEGRO R, FORMOSO G, COPPOLA L, PRESICCE G, MANGIERI T, PEZZAROSSA A, DAZZI D. Euthyroid women with autoimmune disease undergoing assisted reproduction technologies: the role of autoimmunity and thyroid function. *J Endocrinol Invest* 2007; 30: 3-8.
- 55) RESCH U, HELSEL G, TATZBER F, SINZINGER H. Antioxidant status in thyroid dysfunction. *Clin Chem Lab Med* 2002; 40: 1132-1134.
- 56) SEWERYNEK J, WIKTORSKA J, NOWAK D, LEWINSKI A. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease. *Endocr Regulations* 2000; 34: 83-89.